Despite availability of outcome measures and scales for assessing erectile dysfunction (ED) treatment efficacy, guidelines are not available for assessing broader therapeutic outcomes or defining treatment failure in ED. An International Consensus Advisory Panel was convened to develop guidelines, definitions and a new algorithm for evaluating treatment effectiveness in ED. These new guidelines are recommended for use in both research and clinical practice. A multidisciplinary, international panel, consisting of 11 senior researchers and clinicians, was convened to address pertinent issues concerning therapeutic outcome assessment for ED. The panel utilized a modified Delphi method of consensus development and proposed a new model for outcomes assessment. This model is inherently testable, using existing instruments and current methods of assessment. Following a comprehensive literature review and discussion, the Panel recommended adoption of a new treatment effectiveness conceptual framework or theoretical model for assessing therapeutic outcomes in ED. Treatment effectiveness is presumed to be a combined function of two other factors, treatment response and treatment satisfaction. Treatment response is based on the combined assessment of efficacy and tolerability, and treatment satisfaction on the combined assessment of patient and partner satisfaction. Taken together, these two domains define an overall domain of treatment effectiveness. This therapeutic index would be derived by independently assessing treatment efficacy and satisfaction by means of event logs, questionnaires or the more typical patient interview methods. In conclusion, the Ad Hoc Advisory Consensus Panel recommends adoption of a new framework or conceptual model for conducting ED outcome trials or clinical research. The concept of 'treatment effectiveness' is proposed as a new 'umbrella concept' or distal outcome to be evaluated.
Background
The advent of new therapies for erectile dysfunction (ED) and the relative absence of controlled comparator trials has drawn attention to the lack of welldefined guidelines for clinical outcome assessment in comparator studies, or trials of new ED therapies. Therefore, an international advisory panel was convened in conjunction with the annual ISSIR meeting in Montreal, Canada (September, 2002) ; the meeting was sponsored by The University of Medicine & Dentistry of New Jersey (UMDNJ) and the panel comprised invited specialists in urology, psychology and reproductive health with experience in assessing and treating ED. The meeting was convened to develop new guidelines for the evaluation of ED treatment outcomes.
A new concept and model for evaluating treatment effectiveness in ED was developed by the committee. This model is proposed as the basis for future outcome studies and clinical practice assessment in ED. The proposed model is intended specifically for use in:
Clinical trials of new and existing agents. Head-to-head comparator trials. Outcome assessment in clinical practice.
The concept of 'treatment effectiveness', as distinguished from 'treatment efficacy', has been proposed in other therapeutic areas, and is applied increasingly in the evaluation of medical or psychological outcomes research. [1] [2] [3] [4] [5] Treatment effectiveness refers to broader, 'real-world' outcomes assessment that is applicable beyond the narrow limitations of the clinical trial environment. This applies, for example, to the selection of inclusion and exclusion criteria in clinical trials, particularly with regard to partner relationship and other psychosocial variables. It applies equally to selection of study end points. Treatment effectiveness studies typically include measures of treatment adherence and long-term maintenance, in addition to patient expectations and satisfaction with treatment. In a recent, widely cited paper on the need for treatment effectiveness research in mental health, Wells and Sturm noted: 'Policy makers need information on the effectiveness and cost-effectiveness of treatments as typically applied in community settings, because health care should be designed to preserve or promote effective and costeffective treatments' (p. 638).
The overall goal of the present panel was to develop a theoretical model or framework for outcomes evaluation in ED. Our goal was to develop a model that would be simple and generalizable, as well as being potentially applicable to all forms of pharmacologic treatment, regardless of the route of administration or specific mechanism of action (PDE-5, centrally active) of the drug. Despite differences in pharmacological or other attributes of different agents, outcome assessment should always include patient-and partner-oriented measures of treatment satisfaction. The panel noted potential differences between outcomes observed in clinical trial settings, where staff interactions, patient reimbursement and other factors are hypothesized to influence the degree of 'treatment satisfaction' obtained. Again, we have made arguments to support the inclusion of a satisfaction variable as the second major dimension of the proposed model. A key hypothesis of the conceptual model is that it will provide a theoretical framework for predicting patient preference (ie, choice of one treatment over another), as well as treatment compliance/adherence and outcome of treatment in real-life, clinical practice situations.
In addition to broadening greatly the usual inclusion and exclusion criteria, a clinical effectiveness approach, as proposed here, places equal emphasis on patient (and partner) satisfaction. This is in contrast to traditional clinical trial outcome criteria of efficacy and tolerability. In clinical practice, many examples can be cited of discrepancies between pharmacological (or surgical) efficacy of a specific treatment in restoring erectile function per se, and 'real-world' outcomes defined as changes in actual sexual behavior, and patient and/or partner satisfaction. For example, patients who receive surgical implants in a significant number of cases (45% in one recent report), fail to use these devices for sexual intercourse or partner-related activities. Similarly, approximately 50% of patients in several reports have been found to discontinue or avoid the use of intracorporal injections either prior to, or following one or two uses of the drug. Many patients neglect to follow-up on referrals for sex therapy or psychotherapy, and the long-term effectiveness of these treatment has not been adequately evaluated. Taken together, these examples suggest that a clinically relevant assessment of treatment outcome must include measures of patient follow-up and long-term adherence, in addition to assessment of patient and partner satisfaction. This is in contrast to traditional clinical trial-based definitions or outcome designs. 6, 7 In summary:
Clinical trials in ED are generally characterized by:
Motivated patients, with a high degree of compliance in treatment administration and reporting of results. Rigorous criteria for inclusion/exclusion, administration and evaluation. Narrow emphasis on measurable results from the specific treatment under study.
In contrast, clinical practice of ED is characterized by:
Differing expectations and motivation for treatment. Variability among patients in medical and psychological comorbidities, degree of compliance and consistency of reported results. A broad range of possible approaches for managing ED (including counseling and other first-or second-line therapies).
Despite these differences, the panel recommended adoption of uniform outcome criteria for clinical 
Conceptual framework
A new conceptual framework was proposed for assessing treatment effectiveness in ED. This framework would consist of two dimensions:
Treatment response: this dimension refers to pharmacologically based (ie, response-based) aspects, including both treatment efficacy and tolerability (side effects). These effects are typically self-reported by the patient and serve as surrogate end points for objective, physiological changes in penile firmness or rigidity. The 'therapeutic index' has previously been reported as a summary measure of this variable. Treatment satisfaction: this includes both patient and partner subjective responses and overall satisfaction with treatment. Treatment satisfaction may be assessed by means of interview or selfreport questionnaires.
Treatment response
Treatment response refers to a clinically relevant assessment of treatment outcome, in which the alleviation of symptoms is balanced against the tolerance of side effects. Treatment response, as proposed, would consist of a combined or integrated assessment of efficacy of a given treatment, in combination with its tolerability. The panel considered whether side effects (tolerability) of treatment should be incorporated into the response or satisfaction domains. Specific arguments for incorporating tolerability into the treatment response dimension included:
Side effects may be physiologically related to the mechanism of action (eg, vasodilation, smooth muscle relaxation) of the specific treatment agent. Side effects are modifiers of treatment response as they can lead to early treatment discontinuation and/or lack of compliance. Including side effects with the satisfaction dimension would tend to (artificially) elevate efficacy over side effects in the overall evaluation of treatment outcome. Instead, a response dimension would aim to combine these two aspects (efficacy, tolerability) into a single dimension ('treatment response').
Treatment efficacy
The panel agreed that a necessary component of the response dimension is treatment efficacy, as defined by the ability of a pharmacologic agent to promote achievement and maintenance of firm or adequate erections. This ability is most closely tied to the pharmacologic concept of treatment efficacy. Valid assessment of efficacy depends on satisfying certain conditions, such as use of the drug at the highest recommended or tolerated dose to provide an adequate trial of the agent. Depending on the patient's history, lifestyle (eg, availability of partner, frequency of intercourse) and the type of treatment being used, multiple administrations over a specific time period (typically 2-4 weeks) may be required to achieve optimal effects. For oral pharmacotherapy for ED, the panel recommended defining treatment failures or the nonresponder category generally as follows:
''Any patient who, after four successive or closely timed trials of the maximum tolerated dose of the medication, in accordance with the regulatory agency's guidelines with respect to timing relative to meals, alcohol ingestion, use of concomitant medications and adequate sexual stimulation, is unable to achieve or sustain adequate penile rigidity until completion of sexual performance''.
The panel recommended the categories of 'complete responder,' 'partial responder' and 'nonresponder' (as described below) as the major categories of outcome for treatment response. The panel considered but rejected proposals to categorize treatment response solely on the basis of specific scores on a given instrument (eg, international index of erectile function (IIEF)-EF Domain score 425). In part, this is because 'normal' sexual function is age-dependent and typically varies with other demographic or medical risk factors. Additionally, questionnaire measures such as the IIEF may also not be suitable for use in routine clinical practice.
Complete response. This term describes consistent achievement and maintenance of full erection with the ability to engage and complete sexual intercourse. Such erectile response for ED patients is synonymous with 'complete or nearly complete remission of all symptoms'.
The panel agreed that complete response should include the patient's ability to tolerate side effects, without necessarily including the use of concomitant medication for side-effect relief, if any, at the clinically effective dose. Side-effect profiles in this Partial response. This category is regarded as the most difficult to define, and is also likely to include a large proportion of patients. As with the discussion of complete response, the possibility of basing the definition of partial response on specific scale scores was considered, although a broader definition was selected. There was general agreement that partial response refers to a degree of symptom improvement and/or partial remission of symptoms, as described below 1. Achievement of a degree of erection that is clearly discernible, but not adequate for intercourse or complete, or 2. Ability to achieve full erection, but not on a consistent basis over time. 3. Ability to achieve full erection, which is not maintained until completion of intercourse on a consistent basis.
The role of side effects in defining partial response was considered. The panel included in the definition of a partial responder any patient for whom treatment efficacy was adequate, but who was bothered by the side effects of treatment. Side effects were deemed in this case to be, significantly interfering with patient's use of the treatment.
Patients who had adequate efficacy with a given agent or dose, but were reluctant to use the drug due to bothersome side effects of treatment (eg, headache, dyspepsia) were defined as having a partial response to treatment.
Nonresponse. This category is relatively straightforward in cases in which treatment fails to produce an ability to achieve and maintain adequate erection for sexual activity, including either slight improvement that makes no clinical difference or results in the patient's status as unchanged/worse.
The panel proposed adding to the nonresponder category patients whose burden of side effects outweighes their therapeutic gain.
Nonresponders, in general:
Fail to respond in a clinically significant manner to the treatment, Experience intolerable side effects at any dosage or Cannot be titrated to a dose that would produce a response, due to intolerable side effects associated with treatment.
Efficacy assessment
Efficacy assessment methods include the use of event-log or diary-based measures, such as the sexual encounter profile (SEP), the 15-item IIEF, a 
ED treatment response: an integrated outcome
According to the proposed model, treatment efficacy and tolerability can be graphically represented as two independent determinants of a combined or integrated treatment response outcome. As illustrated in Figure 1 , varying degrees of tolerability and efficacy can be conceptualized as producing differences in the overall level of treatment response. The shape of this hypothetical curve reflects the low level of anticipated treatment response when tolerability or efficacy effects are low, but an accelerating response curve in the presence of higher levels of tolerability and efficacy. It should be noted that efficacy and satisfaction are being represented based on three-point scales of intensity Figure 1 Treatment response.
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(low, moderate, high), whereas these domains can be easily shown as four-point, or possibly even fivepoint scales. Further research is strongly recommended to evaluate the respective psychometric properties of these scales.
Treatment satisfaction
Treatment satisfaction can be defined as the degree to which the effects of a specific treatment agent match or exceed the expectations of a given patient and his partner. This variable is intrinsically subjective, and can only be assessed by means of an interview or self-report questionnaire (eg, erectile dysfunction index of treatment satisfaction-EDITS Scale). There was strong consensus in the panel that:
The satisfaction domain should incorporate interpersonal and other nonpharmacologic aspects of the patient's experience with the treatment agent. Assessment of this dimension should be based on subjective criteria, including the patient's and partner's needs and expectations regarding treatment.
As with the response dimension above, the panel agreed that global categories (ie, satisfied or dissatisfied) are insufficient to represent adequately outcomes in this dimension. Again, the panel recommended inclusion of at least three categories of treatment satisfaction (ie, complete satisfaction, partial satisfaction, no satisfaction). These categories are defined briefly as follows.
Complete satisfaction
Patient alone, or in case of existing relationship, patient and his partner are both satisfied. Patient is likely to continue and a willing participant in continued use of the treatment.
Partial satisfaction
In general, this category includes either patients or partners who are not happy with the treatment outcome and therefore skeptical of using the treatment regularly. This may include a number of outcomes, or reasons for lack of complete satisfaction:
Patient satisfied with treatment response, but uncomfortable with regular use of the drug (eg, safety concerns, or fear of dependency). Patient satisfied with treatment response, but not with pharmacokinetic profile (eg, time to onset), food interaction effects or other pharmacologic characteristics of the treatment. Patient satisfied, but partner dissatisfied with use of the drug for any reason (eg, safety fears, feelings of artificiality).
No satisfaction (dissatisfied)
Patient alone, or in the case of an existing relationship, neither the patient nor the partner is satisfied with the outcome of treatment for any reason.
Treatment satisfaction: an integrated outcome
As with the first response domain, treatment satisfaction can be conceptualized as the combined outcome associated with varying degrees of patient and partner satisfaction (See Figure 2) . As shown in the figure, patient and partner satisfaction can be represented as independent determinants of overall treatment satisfaction. The shape of this hypothetical curve reflects the low level of overall treatment satisfaction when patient satisfaction levels are low, but an accelerating response curve when both patient and partner satisfaction levels are high. We have purposely shown the domains as 3-point scales, although one could represent these domains as 4-point or 5-point scales, as above. Again, there is a need for further research to evaluate the specific psychometric properties of these scales.
Treatment effectiveness
According to the proposed model, treatment effectiveness refers to the combined outcome of treatment response and treatment satisfaction, as defined Pharmacologic therapies for ED C Carson et al above. In other words, an overall measure of treatment effectiveness would take into account the combined criteria of efficacy and tolerability (treatment response), along with self-ratings of both patient and partner satisfaction (treatment satisfaction). In the case of a single man without a steady partner relationship, a patient satisfaction score in isolation could be used. Again, two dimensions of treatment response and satisfaction can be conceptualized as producing a combined or integrated measure of treatment effectiveness. Conversely, treatment effectiveness can be defined as the combined product of both treatment response and satisfaction. Treatment effectiveness, for example, is predicted to be the major determinant of drug preference and long-term adherence to treatment (See Figure 3) .
With each level or domain of this model, a key question is the choice of metric to be employed. The type of instrument used (diary, event log, self-report questionnaire) can also vary from one study to another. For the sake of simplicity and to make the concept clear, we have represented each domain as consisting of a 3-point scale. This is shown just for convenience, and could equally be shown with 4-point or 5-point scales on each dimenstion. Specific models could be set up and tested with replication across studies, drug types and treatment populations.
Commentary and discussion
An international consensus panel addressed the definition and classification of therapeutic outcomes in ED. The panel recommended adoption of a 'treatment effectiveness' model, which would incorporate both the traditional outcomes of safety and efficacy, and also patient and partner satisfaction (treatment satisfaction). These four domains are conceptualized as interacting on two dimensions (response, satisfaction). The proposed model is a theoretical framework for predicting patient preference and adherence to treatment. In particular, we propose that an adequate assessment of the domains of efficacy, tolerability, patient satisfaction and partner satisfaction will provide the optimal basis for predicting preference for one form of treatment over another, as well as predicting long-term maintenance or outcomes associated with the use of one treatment compared to another. Treatment dropouts, according to this model, can be predicted if all four domains are adequately assessed and combined in an appropriate model. It should be emphasized that this is only a theoretical model at present, and that actual clinical data are required to provide empirical support for the model.
Treatment efficacy, as measured by validated instruments such as the SEP or IIEF, is the first important component of the overall response to treatment (Figure 4 ). Drug tolerability is equally important, however, in evaluating the clinical effectiveness of the drug. It is included, in combination with efficacy, in the definition of the new category of 'treatment response'. This is the physiological response of the individuals to the pharmacological properties of the drug. Three categories of this dimension (complete responder, partial responder, nonresponder) have been defined. Overall, the response dimension incorporates the pharmacophysiological effects of the drug in achieving adequate erection in the absence of intolerable side effects.
A second dimension, 'treatment satisfaction' is also defined. This consists of the product of two further elements, 'patient satisfaction' and 'partner satisfaction', in cases of an existing relationship. Treatment satisfaction can be assessed by means of either structured self-report, questionnaires (eg, EDITS) or GAQ methods. The scaling and weights to be accorded to these dimensions will depend on results to be obtained in future studies. The present Figure 3 Treatment effectiveness. Figure 4 Efficacy index.
Pharmacologic therapies for ED C Carson et al paper is intended to advance a conceptual or theoretical model; the specific attributes or quantitative scaling of the dimensions will remain to be determined in future studies. The dimension of treatment satisfaction is given a prominent role in the proposed model, since patient satisfaction is hypothesized to effect the maintenance of treatment gains, as well as influencing initial acceptance of treatment. In this respect, we are hypothesizing that treatment satisfaction will be a major determinant of overall treatment effectiveness.
In evaluating this model, validation studies are needed with actual clinical data sets. In particular, studies of the consistency or reliability of current assessment methods (including both test-retest and internal consistency assessments) are needed as part of their overall instrument validation. Additionally, the predictive value of current methods of assessment (eg, IIEF, SEP, EDITS) needs to be assessed. Finally, studies are needed of the predictive validity of the proposed framework in assessing long-term outcomes of ED therapy.
Some limitations of the model should be noted. First, it assumes approximately equal degrees of influence of the two major domains (treatment response, satisfaction), and also approximately equal levels of influence of the subdomains of treatment response (efficacy, tolerability) and satisfaction (patient satisfaction, partner satisfaction). These are testable assumptions, which can be experimentally evaluated with large databases, particularly in long-term outcome studies. Mathematical models can be developed, and subsequently tested using data obtained in clinical trials. This has been proposed for the upcoming European preference trials of current PDE-5 inhibitors (sildenafil, vardenafil, tadalafil). Finally, the term 'effectiveness' lacks precise translation in each language. The major implication of the term, as used here, is that outcomes evaluation in ED should be broadly based, and include components of tolerability, patient satisfaction and, in most instances, partner satisfaction. The term 'effectiveness' is intended to incorporate these various elements, to the extent possible, in a single integrated index or measure of treatment outcome.
The model presents challenges and opportunities for use in clinical practice. Although there are only two major factors, and two particular levels within each factor, primary care physicians are most likely to emphasize patient satisfaction as the basic outcome of treatment. Regulatory and academic investigators, in contrast, will likely continue to emphasize safety and efficacy assessments. The proposed model takes into account these different needs or emphases.
Most importantly, the model provides a framework for evaluating preferences and outcomes associated with pharmacological treatments for ED. This area will undoubtedly attract significant numbers of treatment preference and outcome studies in the coming year, and the proposed model is proposed as a guidance in this regard.
With these limitations in mind, a new model that has been proposed for evaluating treatment effectiveness was strongly endorsed by a consensus panel of international experts in ED. This new framework is intended to provide a broader and more clinically relevant approach to outcomes assessment in the pharmacological treatment of ED. We recommend that it be experimentally tested in the context of upcoming comparator trials in ED and be used specifically as a framework for evaluating adherence and patient selection factors in these trials. The model may also be of value in educating physicians and other health care clinicians in the clinical management of ED.
